Actualizado Reviewed

Management of Medication Toxicity or Intolerance

Nephrotoxic Effects

View full version of Table 17i.
Table 17i. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
Table 17i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
  
  
  
  

References

  1. Al Hammond R, Kalaskar A, Rodriguez G, et al. Microalbuminuria in perinatally HIV-infected children and adolescents in the United States. Open Forum Infect Dis. 2023;10(7):ofad333. Available at: https://pubmed.ncbi.nlm.nih.gov/37426950.
  2. Aliyannissa A, Kuswiyanto RB, Setiabudi D, Nataprawira HM, Alam A, Sekarwana N. Correlation between CD4 count and glomerular filtration rate or urine protein:creatinine ratio in human immunodeficiency virus–infected children. Kidney Res Clin Pract. 2020;39(1):40-46. Available at: https://pubmed.ncbi.nlm.nih.gov/32146732.
  3. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus–infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28(7):619-625. Available at: https://pubmed.ncbi.nlm.nih.gov/19561425.
  4. Beng H, Rakhmanina N, Moudgil A, et al. HIV-associated CKDs in children and adolescents. Kidney Int Rep. 2020;5(12):2292-2300. Available at: https://pubmed.ncbi.nlm.nih.gov/33305123.
  5. Bk K, Tiwari S, Chhapola V, Debnath E, Seth A, Jain A. Brief report: subclinical kidney dysfunction in HIV-infected children: a cross-sectional study. J Acquir Immune Defic Syndr. 2020;85(4):470-474. Available at: https://pubmed.ncbi.nlm.nih.gov/33136747.
  6. Brunel V, Massy N, Malval B. Atazanavir urolithiasis without recent intake of atazanavir. Ann Biol Clin (Paris). 2019;77(4):459-460. Available at: https://pubmed.ncbi.nlm.nih.gov/31418708.
  7. Bunupuradah T, Phupitakphol T, Sophonphan J, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai adolescents. Pediatr Infect Dis J. 2018;37(1)66-70. Available at: https://pubmed.ncbi.nlm.nih.gov/28719505.
  8. Campbell L, Barbini B, Burling B, et al. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disproxil fumarate. J Acquir Immune Defic Syndr. 2021;88(2):214-219. Available at: https://pubmed.ncbi.nlm.nih.gov/34506361.
  9. de Lastours V, Ferrari Rafael De Silva E, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68(8):1850-1856. Available at: https://pubmed.ncbi.nlm.nih.gov/23599359.
  10. Ekulu PM, Nkoy AB, Betukumesu DK, et al. APOL1 risk genotypes are associated with early kidney damage in children in sub-Saharan Africa. Kidney Int Rep. 2019;4(7):930-938. Available at: https://pubmed.ncbi.nlm.nih.gov/31317115.
  11. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32-40. Available at: https://pubmed.ncbi.nlm.nih.gov/22732469.
  12. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455-1465. Available at: https://pubmed.ncbi.nlm.nih.gov/30932951.
  13. Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24(4):525-534. Available at: https://pubmed.ncbi.nlm.nih.gov/20139752.
  14. Lim Y, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally-acquired HIV infection: a single-centre cohort study. Clin Drug Investig. 2015;35(5):327-333. Available at: https://pubmed.ncbi.nlm.nih.gov/25861908.
  15. Lin KY, Liao SH, Liu WC, et al. Cholelithiasis and nephrolithiasis in HIV-positive patients in the era of combination antiretroviral therapy. PLoS One. 2015;10(9):e0137660. Available at: https://pubmed.ncbi.nlm.nih.gov/26360703.
  16. Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA. Is abnormal urine protein/osmolality ratio associated with abnormal renal function in patients receiving tenofovir disoproxil fumarate? PLoS One. 2016;11(2):e0149562. Available at: https://pubmed.ncbi.nlm.nih.gov/26872144.
  17. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med. 2009;163(2):164-171. Available at: https://pubmed.ncbi.nlm.nih.gov/19188649.
  18. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One. 2013;8(10):e77268. Available at: https://pubmed.ncbi.nlm.nih.gov/24130871.
  19. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32(5):495-500. Available at: https://pubmed.ncbi.nlm.nih.gov/23249917.
  20. Purswani MU, Patel K, Winkler CA, et al. Brief report: APOL1 renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. J Acquir Immune Defic Syndr. 2016;73(1):63-68. Available at: https://pubmed.ncbi.nlm.nih.gov/27035887.
  21. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J. 2009;28(3):204-209. Available at: https://pubmed.ncbi.nlm.nih.gov/19209091.
  22. Samarawickrama A, Cai M, Smith ER, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. HIV Med. 2012;13(9):526-532. Available at: https://pubmed.ncbi.nlm.nih.gov/22413854.
  23. Seo JW, Kim K, Jun KI, et al. Recovery of tenofovir-induced nephrotoxicity following switch from tenofovir disoproxil fumarate to tenofovir alafenamide in human immunodeficiency virus–positive patients. Infect Chemother. 2020;52(3):381-388. Available at: https://pubmed.ncbi.nlm.nih.gov/32757496.
  24. de Sousa Soares D, Cavalcante MG, Ribeiro SMV, et al. Acute kidney injury in HIV-infected children: comparison of patients according to the use of highly active antiretroviral therapy. J Pediatr (Rio J). 2016;92(6):631-637. Available at: https://pubmed.ncbi.nlm.nih.gov/27542916.
  25. Soler-Palacín P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25(2):171-176. Available at: https://pubmed.ncbi.nlm.nih.gov/21076275.

Management of Medication Toxicity or Intolerance

Nephrotoxic Effects

View full version of Table 17i.
Table 17i. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
Table 17i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
  
  
  
  

Download Guidelines

Related Content